• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Safety and Viability of Immunotherapy Delivery at a Regional Queensland Centre

    Author(s)
    Gunawan, Ben
    Chan, Bryan A
    Azer, Mary
    Griffith University Author(s)
    Chan, Bryan
    Year published
    2017
    Metadata
    Show full item record
    Abstract
    Aims: Oncology has been revolutionised by the expanding indications for checkpoint inhibitors (CPI). It is critical that patients from non‐metropolitan centres have access to these drugs to minimise healthcare inequality. We aimed to assess the safety and viability of immunotherapy delivery at a regional centre in Queensland. Methods: A retrospective analysis was performed for all patients with advanced solid tumour malignancies receiving a CPI between 2013 and 2017. Patient details including primary malignancy, CPI used, duration of treatment and reason for cessation were captured. The incidence, type, grade and management ...
    View more >
    Aims: Oncology has been revolutionised by the expanding indications for checkpoint inhibitors (CPI). It is critical that patients from non‐metropolitan centres have access to these drugs to minimise healthcare inequality. We aimed to assess the safety and viability of immunotherapy delivery at a regional centre in Queensland. Methods: A retrospective analysis was performed for all patients with advanced solid tumour malignancies receiving a CPI between 2013 and 2017. Patient details including primary malignancy, CPI used, duration of treatment and reason for cessation were captured. The incidence, type, grade and management of immune‐related adverse events (IRAEs) were compared to published data. Results: Of 74 patients, the median age at commencement was 64.5years (range 38–81). Non–small cell lung cancer (45%) and melanoma (45%) were the most common primary tumours. Median number of treatment cycles (excluding ipilimumab) was five (range 1–68) at data cutoff. Twenty‐one patients (29%) had at least one IRAE. Of the total 33 IRAEs, rash/dermatitis was the most common (27%), followed by thyroid dysfunction (15%) and colitis (15%). Most documented IRAEs were grade 2 (48.5%); grade 1 (36.5%) and grade 3 (15%); there were no grade 4 or 5 events. Management of IRAEs was consistent with manufacturer and published guidelines. Corticosteroids were employed in all grade 2/3 IRAEs and subspecialist consultation was sought in all grade 3 IRAE. The most common reason for discontinuation of treatment was terminal decline (38%), or progressive disease (25%). Conclusions: At our regional centre in Queensland, the use of CPI for advanced solid tumour malignancies has rapidly increased. Our review suggests that CPI can be safely administered at a regional centre, with the incidence of IRAEs similar to published phase III data and management consistent with established guidelines. Future studies should consider comparing the outcomes between metropolitan and regional centres for CPI therapy.
    View less >
    Conference Title
    Asia-Pacific Journal of Clinical Oncology
    Volume
    13
    Publisher URI
    https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.12799
    Subject
    Oncology and carcinogenesis
    Science & Technology
    Life Sciences & Biomedicine
    Oncology
    Publication URI
    http://hdl.handle.net/10072/403955
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E
    • TEQSA: PRV12076

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander